Bai Aotai (688177.SH): Usoonumab injection obtained positive opinions from the Committee for Medicinal Products for Human Use of the European Medicines Agency.

Intelligence Finance APP news, BaiAotai (688177.SH) announced that the company recently received a notification from the European Medicines Agency (EMA) that Usymro (BAT2206, ustekinumab injection) has received a positive opinion from the EMA Human Medicines Committee (CHMP). CHMP recommended that the European Commission (EC) approve the listing of Usymro for the treatment of moderate to severe plaque psoriasis (PsO) in adults and children, active psoriatic arthritis (PsA), and moderate to severe active Crohn's disease (CD).